Pfizer-BNT vaccine. An article with data on protection and safety has been published, and not only …

The second important news today, also concerning this vaccine, is that the issue of issuing an FDA approval for its use has practically been resolved. Today the Advisory Committee voted to issue an Emergency Use Authorization (EUA) for the vaccine. 17 members of the committee voted “for”, “against” – 4 and one abstained. This practically prejudges a positive FDA decision that will take place in the coming days. Similar approval for the use of the Pfizer-BNT vaccine has already been received from national regulators in the United Kingdom and Canada. Most likely, the European regulator (EMA) will soon follow their example.

 

 

About the article. While I looked through it fluently. The first impression is that the quality of the trials of the BNT162b2 vaccine is higher than in the case of the AstraZeneka vaccine. The results for the protective efficacy against disease for BNT162b2 are also better and more convincing than those for AZD1222. However, the BNT162b2 vaccine has not been tested for protection against SARS-CoV-2 infection. The article provides detailed safety data. In general, everything is within the expected – transient local “adverse events” (AE); of common HI weakness, headache and fever, also transient. This appears to be better in frequency than the comparable Moderna vaccine, but we have to wait for a similar publication for this vaccine. I think it will appear very soon.Поділитися цим:

0

Автор публікації

Офлайн 2 місяці

Amir0406

0
Коментарі: 0Публікації: 20Реєстрація: 18-01-2021

You may also like...

Залишити відповідь

Войти с помощью: 

Ваша e-mail адреса не оприлюднюватиметься.

Авторизація
*
*
Войти с помощью: 
Реєстрація
*
*
*
Войти с помощью: 
Генерація паролю